|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2009-4-7
|
|
pubmed:abstractText |
A phase II randomized controlled trial of recombinant human relaxin suggested that a dosage of 25 microg/kg/day was safe and clinically effective in improving skin disease and reducing functional disability in scleroderma (systemic sclerosis; SSc). We undertook a large randomized, double-blind, placebo-controlled clinical trial to compare placebo with 10 microg/kg/day and 25 microg/kg/day recombinant human relaxin, given for 24 weeks in patients with stable, diffuse, moderate-to-severe SSc.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0004-3591
|
|
pubmed:author |
pubmed-author:ClementsPhilip JPJ,
pubmed-author:CollierDavidD,
pubmed-author:CsukaMary EME,
pubmed-author:EllmanMichaelM,
pubmed-author:FiresteinGary SGS,
pubmed-author:FurstDaniel EDE,
pubmed-author:KavanaughArthur FAF,
pubmed-author:KhannaDineshD,
pubmed-author:KimYoun HYH,
pubmed-author:KornJoseph HJH,
pubmed-author:MaranianPaulP,
pubmed-author:MayesMaureen DMD,
pubmed-author:MedsgerThomas ATAJr,
pubmed-author:MerkelPeter APA,
pubmed-author:MorelandLarry WLW,
pubmed-author:Relaxin Investigators and the Scleroderma Clinical Trials Consortium,
pubmed-author:RothfieldNaomiN,
pubmed-author:SandersMartin EME,
pubmed-author:SeiboldJames RJR,
pubmed-author:SilverRichardR,
pubmed-author:SimmsRobertR,
pubmed-author:SteenVirginia DVD,
pubmed-author:WeismanMichaelM,
pubmed-author:WigleyFredrick MFM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
60
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1102-11
|
|
pubmed:dateRevised |
2011-8-1
|
|
pubmed:meshHeading |
pubmed-meshheading:19333948-Adult,
pubmed-meshheading:19333948-Creatinine,
pubmed-meshheading:19333948-Dose-Response Relationship, Drug,
pubmed-meshheading:19333948-Double-Blind Method,
pubmed-meshheading:19333948-Female,
pubmed-meshheading:19333948-Humans,
pubmed-meshheading:19333948-Infusions, Subcutaneous,
pubmed-meshheading:19333948-Male,
pubmed-meshheading:19333948-Middle Aged,
pubmed-meshheading:19333948-Placebos,
pubmed-meshheading:19333948-Recombinant Proteins,
pubmed-meshheading:19333948-Relaxin,
pubmed-meshheading:19333948-Scleroderma, Systemic,
pubmed-meshheading:19333948-Skin,
pubmed-meshheading:19333948-Substance Withdrawal Syndrome,
pubmed-meshheading:19333948-Treatment Failure,
pubmed-meshheading:19333948-Vital Capacity
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.
|
|
pubmed:affiliation |
David Geffen School of Medicine, and School of Public Health, University of California, Los Angeles, USA. dkhanna@mednet.ucla.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
